Skip to main content
Clinical Trials/IRCT20201128049515N1
IRCT20201128049515N1RecruitingPhase 2

The efficacy and safety of Silymarin in chemotherapy-induced peripheral neuropathy (CIPN): a randomized double-blind clinical trial study

Mazandaran University of Medical Sciences0 sites80 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Histologically confirmed diagnosis of cancer
  • At least 18 years of age
  • Having chemotherapy-induced peripheral neuropathy (CIPN).

Exclusion Criteria

  • Having a known disease predisposing to neuropathy, including diabetes, neuromuscular disease, vitamin B12 deficiency, amyloidosis, and connective tissue disease, a history of neurological diseases such as hereditary and acquired neuropathies
  • Unbearable side effects of the drug or drug reaction
  • Taking any antioxidant supplement in the last two months
  • Pregnancy, or breastfeeding
  • unwillingness to attend the study

Investigators

Similar Trials